The Ohio State University, Columbus, Ohio 43210, USA.
J Med Chem. 2010 Mar 25;53(6):2494-501. doi: 10.1021/jm901778v.
Peptidylprolyl isomerase Pin1 regulates the function and/or stability of phosphoproteins by altering the conformation of specific pSer/pThr-Pro peptide bonds. In this work, a cyclic peptide library was synthesized and screened against the catalytic domain of human Pin1. The selected inhibitors contained a consensus motif of D-pThr-Pip-Nal (where Pip is L-piperidine-2-carboxylic acid and Nal is L-2-naphthylalanine). Representative compounds were tested for binding to Pin1 by isothermal titration calorimetry and inhibition of Pin1 activity, and the most potent inhibitors had K(D) (and K(I)) values in the low nanomolar range. Treatment of breast cancer cells with the inhibitors, which were rendered membrane permeable by attachment of an octaarginine sequence, inhibited cell proliferation and increased the protein levels of two previously established Pin1 substrates, PML and SMRT. Finally, a second generation of cell permeable Pin1 inhibitors was designed by replacing the noncritical residues within the cyclic peptide ring with arginine residues and shown to have antiproliferative activity against the cancer cells.
肽基脯氨酰顺反异构酶 Pin1 通过改变特定 pSer/pThr-Pro 肽键的构象来调节磷酸化蛋白的功能和/或稳定性。在这项工作中,合成了一个环肽文库,并针对人源 Pin1 的催化结构域进行了筛选。所选抑制剂包含 D-pThr-Pip-Nal 的共有基序(其中 Pip 是 L-哌啶-2-羧酸,Nal 是 L-2-萘丙氨酸)。代表性化合物通过等温滴定量热法测试与 Pin1 的结合以及对 Pin1 活性的抑制作用,最有效的抑制剂的 K(D)(和 K(I))值在纳摩尔范围内。用通过连接八聚精氨酸序列而具有膜通透性的抑制剂处理乳腺癌细胞,抑制细胞增殖并增加先前确定的两个 Pin1 底物 PML 和 SMRT 的蛋白水平。最后,通过用精氨酸取代环肽环内的非关键残基设计了第二代细胞通透性 Pin1 抑制剂,并显示出对癌细胞的抗增殖活性。